Stereotaxis, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Stereotaxis, Inc. on September 22, 2016, regarding events occurring between September 21 and September 26, 2016. The filing details a material definitive agreement for a private placement offering, the termination of an existing loan agreement, and changes to the Board of Directors.
Key Financial Metrics and Transaction Details
- Offering Size: Aggregate purchase price of $24 million.
- Net Proceeds: Approximately $23.1 million after offering expenses.
- Debt Repayment: $13 million of proceeds will be used to fully satisfy outstanding indebtedness to Healthcare Royalty Partners II, L.P. (HRP).
- Securities Issued:
- 24,000 shares of Series A Convertible Preferred Stock (par value $0.001, stated value $1,000).
- Warrants to purchase 36,923,077 shares of Common Stock.
- Preferred Stock Terms: 6.0% cumulative annual dividend (accrued, not paid in cash unless liquidation/redemption occurs); initial conversion price of $0.65 per share.
- Warrant Terms: Exercise price of $0.70 per share; exercisable for five years from closing.
Material Changes and Corporate Actions
- Debt Termination: The Company will terminate its Loan Agreement with HRP upon closing the offering, paying off the full outstanding balance.
- Board Composition Changes:
- Board size increased from eight to nine directors.
- Resignations: Euan S. Thomson, Ph.D. (effective Sept 22) and Joseph D. Keegan, Ph.D. (effective Sept 29).
- Appointments: David Fischel, Joseph Kiani, and Arun Menawat, Ph.D. appointed as new directors effective at closing.
- Investor Rights: Buyers have pro rata participation rights in future equity financings for 61 months, provided at least 8,000 Preferred Shares remain outstanding.
Guidance, Risks, and Contingencies
- Closing Conditions: The offering is contingent on the payment of the $13 million HRP debt and other customary conditions. Closing is anticipated on or about September 29, 2016.
- Registration Rights: The Company must file a resale registration statement within 45 days of closing and have it declared effective within 120 days. Failure to meet these deadlines triggers liquidated damages of 1.5% of the aggregate value of shares, accruing interest at 1.5% per month.
- Liquidated Damages (Issuance): Failure to timely issue shares or remove legends may result in damages of 0.25% of the product of the number of shares and the weighted average stock price.
- Forward-Looking Statements: The filing includes standard disclaimers regarding the uncertainty of closing the offering and future operating results.
Key Facts for Investor Verification
- Confirm the actual closing date of the offering (anticipated Sept 29, 2016) and the receipt of net proceeds.
- Verify the full repayment of the HRP loan and the termination of the associated agreement.
- Monitor the filing and effectiveness of the resale registration statement for the Conversion Shares and Warrant Shares within the 120-day deadline to avoid liquidated damages.
- Review the impact of the new Board Designees on corporate governance and committee assignments.
- Assess the dilution impact of the 36.9 million warrant shares and the conversion of 24,000 preferred shares (at $0.65/share) on existing shareholders.